SLC7A5 and cancer: Therefore, if LAT1 is upregulated with smaller clinically relevant amounts and in a long term use, there is a risk that there will not be enough LAT1-inhibitor to starve the cancer cells at the end, which may then result in insufficient antiproliferative efficacy of LAT1-inhibitor.